Actively Recruiting
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Led by Repurposed Therapeutics, Inc. · Updated on 2024-05-17
30
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
Sponsors
R
Repurposed Therapeutics, Inc.
Lead Sponsor
N
National Aeronautics and Space Administration (NASA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).
CONDITIONS
Official Title
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects must report at least two responses of "Sometimes" or "Frequently" on the Motion Sickness Susceptibility Questionnaire
- No neurologic, vestibular, or autonomic disorders
- No medical conditions worsened by scopolamine such as narrow-angle glaucoma or urinary retention
- Negative COVID-19 test within 7 days before drug administration or no symptoms up to 10 days before drug administration
- Age between 18 and 65 years
You will not qualify if you...
- Taking drugs that affect the central nervous system, like antihistamines, tricyclic antidepressants, or muscle relaxants
- Hypersensitivity to scopolamine, belladonna alkaloids, or any ingredient in the formulation or delivery system
- Pregnant women or women with a positive pregnancy test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NASA Johnson Space Center Neuroscience Laboratory
Houston, Texas, United States, 77058
Actively Recruiting
Research Team
B
Barry Feinberg, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here